---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015505"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:36:40.996758+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement

## Summary
- Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.
- Cash, equivalents and marketable securities $292.7M; expects sufficient for two years.
- Filed patent infringement suit against Pfizer over Paxlovid; seeks damages, not injunction; patent awarded June 2022.
- EDP-235 Phase 1 data positive; Phase 2 study planned Q4 2022; RSV programs include new Phase 2 studies for EDP-938 and EDP-323.
- Appointed Scott T. Rottinghaus as SVP and Chief Medical Officer.

## SEC filing metadata
- accession: 0000950170-22-015505
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/0000950170-22-015505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/enta-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015505
- JSON: https://secwatch.observer/filing/0000950170-22-015505.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.